Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PROK

ProKidney Corp

Sep 20 • 04:00PM ET

2.46

Dollar change +0.07
Percentage change 2.93	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWN SCHA SBIO VTWG RSSL

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	39.18%	Shs Outstand	126.05M	Perf Week	2.93%
Market Cap	310.08M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	166.99%	Shs Float	76.66M	Perf Month	2.93%
Income	-38.68M	PEG	-	EPS next Q	-0.13	Inst Own	36.58%	Short Float	13.17%	Perf Quarter	-1.60%
Sales	0.00M	P/S	-	EPS this Y	12.21%	Inst Trans	1.71%	Short Ratio	17.15	Perf Half Y	79.56%
Book/sh	-7.73	P/B	-	EPS next Y	-5.20%	ROA	-7.87%	Short Interest	10.10M	Perf Year	-47.55%
Cash/sh	3.42	P/C	0.72	EPS next 5Y	-	ROE	-	52W Range	1.12 - 5.29	Perf YTD	38.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-53.50%	Beta	1.31
Dividend TTM	-	Quick Ratio	21.87	Sales past 5Y	0.00%	Gross Margin	-	52W Low	119.64%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	21.87	EPS Y/Y TTM	0.59%	Oper. Margin	0.00%	RSI (14)	56.40	Volatility	7.04% 7.23%
Employees	163	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	4.80
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-16.71%	Payout	-	Rel Volume	16.10	Prev Close	2.39
Sales Surprise	-	EPS Surprise	36.76%	Sales Q/Q	-	Earnings	Aug 09 BMO	Avg Volume	589.03K	Price	2.46
SMA20	4.86%	SMA50	7.96%	SMA200	16.13%	Trades		Volume	9,485,050	Change	2.93%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-24	Initiated	Guggenheim	Buy	$6
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight	$3
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy	$16
Dec-21-22	Initiated	Jefferies	Buy	$15
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight	$13
Oct-18-22	Initiated	UBS	Buy	$18
Oct-14-22	Initiated	Citigroup	Buy	$16
Sep-23-22	Initiated	BofA Securities	Buy	$14
Sep-02-22	Initiated	Evercore ISI	Outperform

Sep-04-24 01:33PM	ProKidney drops Phase III CKD study to focus on US market and save up to $175m (Clinical Trials Arena) -9.17%
Sep-03-24 07:30AM	ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. (GlobeNewswire)
Aug-27-24 07:30AM	ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -7.53%
Aug-09-24 07:00AM	ProKidney Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-27-24 05:52AM	PROK Stock Earnings: ProKidney Reported Results for Q4 2023 (InvestorPlace) +6.61%
02:10PM	Loading…
Jun-26-24 02:10PM	Hedge Fund and Insider Trading News: Crispin Odey, Boaz Weinstein, Ken Griffin, Greenlight Capital, Eisler Capital, ProKidney Corp (PROK), Essex Property Trust Inc (ESS), and More (Insider Monkey)
Jun-17-24 07:00AM	ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters' Option (GlobeNewswire) +6.96%
Jun-11-24 09:35PM	ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -19.87% +23.55%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-10-24 04:15PM	ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering (GlobeNewswire) -5.33%
07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates (GlobeNewswire)
May-29-24 07:00AM	ProKidney to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.74%
May-21-24 07:00AM	ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 (GlobeNewswire)
May-10-24 03:43PM	ProKidney Corp Reports First Quarter 2024 Financial Results (GuruFocus.com) +7.66%
01:54PM	Loading…
01:54PM	PROK Stock Earnings: ProKidney Beats EPS for Q1 2024 (InvestorPlace)
07:48AM	ProKidney Q1 Loss Unchanged From Year Earlier (MT Newswires)
07:00AM	ProKidney Reports Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Mar-25-24 06:05AM	ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations (GlobeNewswire)
Mar-21-24 07:49PM	ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.16%
Feb-29-24 04:05PM	ProKidney to Participate in Jefferies Biotech on the Bay Summit (GlobeNewswire)
Dec-29-23 08:22AM	Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years (Insider Monkey)
Dec-13-23 09:55AM	Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.60%
Nov-30-23 06:05AM	ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer (GlobeNewswire) -10.16%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-21-23 06:05AM	ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference (GlobeNewswire) +5.68%
Nov-17-23 01:38PM	ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-16-23 09:35AM	After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK) (Zacks) -11.51%
Nov-14-23 07:04AM	ProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease Trials (GuruFocus.com) -5.00%
06:05AM	ProKidney Reports Third Quarter Financial Results (GlobeNewswire)
05:02PM	Loading…
Nov-13-23 05:02PM	ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ) for Diabetic CKD and Provides Corporate Updates (GlobeNewswire)
Oct-30-23 04:12PM	ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023 (GlobeNewswire) +12.29%
Oct-17-23 09:35AM	ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -7.93%
Oct-16-23 02:50PM	Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock? (InvestorPlace)
Oct-12-23 03:05PM	Why Shares of ProKidney Were Dropping Thursday (Motley Fool) -31.45%
Sep-06-23 12:14PM	ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem (American City Business Journals)
Sep-05-23 06:05AM	ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-31-23 10:33AM	3 Biotech Stocks Due for a Massive Short Squeeze (InvestorPlace)
Aug-29-23 01:16PM	ProKidney confirmed as company seeking incentives to expand in Forsyth County (American City Business Journals)
Aug-11-23 02:21PM	ProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansion (American City Business Journals)
Aug-10-23 04:10PM	ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-18-23 06:05AM	ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jul-17-23 06:05AM	ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization (GlobeNewswire) +6.65%
Jun-13-23 12:05PM	ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC (GlobeNewswire)
Jun-01-23 04:05PM	ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference (GlobeNewswire) -7.66%
May-11-23 04:01PM	ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-04-23 06:05AM	ProKidney to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
Apr-25-23 02:00PM	We're Interested To See How ProKidney (NASDAQ:PROK) Uses Its Cash Hoard To Grow (Simply Wall St.) -8.73%
Mar-28-23 04:12PM	ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.39%
Mar-03-23 06:05AM	ProKidney to Participate in TD Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Jan-11-23 07:48AM	ProKidneys stock jumps 29% (MarketWatch)
Jan-10-23 04:05PM	ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease (GlobeNewswire) +9.57%
Dec-27-22 11:05AM	Chamath Palihapitiya Stocks: 10 Stocks Picked in the Last 10 Years (Insider Monkey) -5.82%
08:46AM	A Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK) (Simply Wall St.)
Dec-22-22 06:05AM	ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference (GlobeNewswire)
Nov-16-22 11:22AM	ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-14-22 06:05AM	ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-11-22 04:05PM	ProKidney to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.85%
Nov-03-22 06:05AM	ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease (GlobeNewswire)
Oct-14-22 12:00PM	ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Sep-23-22 06:15AM	ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-08-22 06:05AM	ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-22 06:05AM	ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations (GlobeNewswire) +12.28%
Aug-11-22 05:30PM	ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.55%
10:01AM	ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox (GlobeNewswire)
Jul-20-22 08:00AM	ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weber Darin J.	Chief Regulatory Officer	Sep 19 '24	Sale	2.50	16,412	41,030	103,480	Sep 20 04:44 PM
DARIN J WEBER	Officer	Sep 19 '24	Proposed Sale	2.39	16,412	39,225		Sep 19 04:27 PM
Weber Darin J.	Chief Regulatory Officer	Jul 26 '24	Sale	2.50	826	2,065	119,892	Jul 29 04:02 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Jun 11 '24	Buy	2.42	8,264,462	19,999,998	71,560,107	Jun 25 04:06 PM
Weber Darin J.	Chief Regulatory Officer	Jun 18 '24	Sale	2.82	17,238	48,616	120,718	Jun 20 04:03 PM
Legorreta Pablo G.	Director	Jun 13 '24	Buy	2.42	22,617,909	54,735,340	22,617,909	Jun 14 04:05 PM
Weber Darin J.	Chief Regulatory Officer	May 20 '24	Sale	4.08	17,238	70,386	137,956	May 22 07:22 AM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Mar 13 '24	Buy	1.50	50,000	75,090	63,168,645	May 16 08:22 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Mar 14 '24	Buy	1.36	50,000	67,925	63,218,645	May 16 08:22 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Mar 20 '24	Buy	1.40	33,000	46,111	63,251,645	May 16 08:22 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Mar 25 '24	Buy	1.43	30,000	42,954	63,295,645	May 16 08:22 PM
Control Empresarial de Capital	Add'l Rep. Persons-see Ex.99-1	Mar 22 '24	Buy	1.40	14,000	19,586	63,265,645	May 16 08:22 PM
Weber Darin J.	SVP of Regulatory Development	Apr 22 '24	Sale	2.51	16,438	41,315	155,194	Apr 23 04:05 PM
Weber Darin J.	SVP of Regulatory Development	Apr 18 '24	Sale	2.54	800	2,028	171,632	Apr 23 04:05 PM
Weber Darin J.	SVP of Regulatory Development	Apr 16 '24	Sale	2.50	17,238	43,095	172,432	Apr 17 06:57 PM
Weber Darin J.	SVP of Regulatory Development	Apr 12 '24	Sale	1.73	84,103	145,498	189,670	Apr 16 04:54 PM
Weber Darin J.	SVP of Regulatory Development	Apr 01 '24	Sale	1.69	300	507	273,773	Apr 16 04:54 PM
Palihapitiya Chamath	Former 10% Owner	Nov 19 '23	Sale	1.31	7,256,367	9,498,584	0	Nov 21 06:30 AM
Palihapitiya Chamath	10% Owner	Nov 15 '23	Sale	1.49	282,300	420,147	5,653,867	Nov 17 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 17 '23	Sale	1.19	258,400	308,400	5,183,367	Nov 17 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 16 '23	Sale	1.22	212,100	259,398	5,441,767	Nov 17 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 14 '23	Sale	1.50	306,200	459,086	5,936,167	Nov 14 09:15 PM
Palihapitiya Chamath	10% Owner	Nov 09 '23	Sale	1.68	95,900	160,700	6,416,967	Nov 14 09:15 PM
Palihapitiya Chamath	10% Owner	Nov 13 '23	Sale	1.57	88,700	139,676	6,242,367	Nov 14 09:15 PM
Palihapitiya Chamath	10% Owner	Nov 10 '23	Sale	1.61	85,900	138,411	6,331,067	Nov 14 09:15 PM
Palihapitiya Chamath	10% Owner	Nov 06 '23	Sale	1.56	79,600	123,818	6,643,100	Nov 08 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 07 '23	Sale	1.59	71,233	113,367	6,571,867	Nov 08 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 08 '23	Sale	1.66	59,000	97,763	6,512,867	Nov 08 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 03 '23	Sale	1.73	148,300	256,470	6,722,700	Nov 03 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 02 '23	Sale	1.73	133,700	231,956	6,871,000	Nov 03 09:00 PM
Palihapitiya Chamath	10% Owner	Nov 01 '23	Sale	1.62	123,400	199,674	7,004,700	Nov 03 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 30 '23	Sale	1.65	157,000	259,537	7,270,000	Oct 31 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 31 '23	Sale	1.69	141,900	239,300	7,128,100	Oct 31 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 27 '23	Sale	1.59	92,500	146,677	7,427,000	Oct 31 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 24 '23	Sale	1.75	176,300	308,613	7,664,673	Oct 26 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 26 '23	Sale	1.80	77,960	140,577	7,519,500	Oct 26 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 25 '23	Sale	1.76	67,213	118,382	7,597,460	Oct 26 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 19 '23	Sale	2.19	200,000	438,700	8,088,473	Oct 23 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 23 '23	Sale	1.83	160,300	293,429	7,840,973	Oct 23 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 20 '23	Sale	1.92	87,200	167,834	8,001,273	Oct 23 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 16 '23	Sale	2.87	215,543	618,630	8,519,973	Oct 18 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 17 '23	Sale	2.83	106,400	301,357	8,413,573	Oct 18 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 18 '23	Sale	2.28	125,100	285,403	8,288,473	Oct 18 09:00 PM
Palihapitiya Chamath	10% Owner	Oct 13 '23	Sale	2.67	250,000	667,525	8,735,516	Oct 13 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 12 '23	Sale	2.69	161,863	436,007	8,985,516	Oct 13 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 11 '23	Sale	3.84	75,000	288,285	9,147,379	Oct 13 09:30 PM
Palihapitiya Chamath	10% Owner	Oct 06 '23	Sale	4.48	75,000	336,360	9,372,379	Oct 10 09:32 PM
Palihapitiya Chamath	10% Owner	Oct 10 '23	Sale	4.34	75,000	325,162	9,222,379	Oct 10 09:32 PM
Palihapitiya Chamath	10% Owner	Oct 09 '23	Sale	4.20	75,000	315,225	9,297,379	Oct 10 09:32 PM
Palihapitiya Chamath	10% Owner	Oct 05 '23	Sale	4.76	52,621	250,718	9,447,379	Oct 10 09:32 PM

Open in Screener

RPRX

Royalty Pharma plc

Sep 20 • 04:00PM ET

27.54

Dollar change -0.45
Percentage change -1.61	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

RPRX Royalty Pharma plc daily Stock Chart

Held by: VTI VO VXF VTV VOE VYM VHT IWR IHE IWD

Index	-	P/E	18.33	EPS (ttm)	1.50	Insider Own	14.69%	Shs Outstand	446.69M	Perf Week	-0.65%
Market Cap	12.34B	Forward P/E	6.27	EPS next Y	4.39	Insider Trans	0.00%	Shs Float	382.30M	Perf Month	-0.22%
Income	672.90M	PEG	5.73	EPS next Q	0.92	Inst Own	70.75%	Short Float	3.84%	Perf Quarter	2.34%
Sales	2.24B	P/S	5.52	EPS this Y	-11.85%	Inst Trans	1.54%	Short Ratio	5.60	Perf Half Y	-9.50%
Book/sh	14.42	P/B	1.91	EPS next Y	11.17%	ROA	3.88%	Short Interest	14.68M	Perf Year	0.33%
Cash/sh	4.02	P/C	6.84	EPS next 5Y	3.20%	ROE	10.56%	52W Range	25.20 - 31.66	Perf YTD	-1.96%
Dividend Est.	0.92 (3.34%)	P/FCF	4.59	EPS past 5Y	2.23%	ROI	4.78%	52W High	-13.00%	Beta	0.46
Dividend TTM	0.83 (3.01%)	Quick Ratio	9.35	Sales past 5Y	5.78%	Gross Margin	-	52W Low	9.29%	ATR (14)	0.51
Dividend Ex-Date	Aug 16, 2024	Current Ratio	9.35	EPS Y/Y TTM	165.78%	Oper. Margin	42.92%	RSI (14)	42.91	Volatility	1.57% 1.66%
Employees	89	Debt/Eq	1.17	Sales Y/Y TTM	-5.25%	Profit Margin	30.07%	Recom	1.33	Target Price	44.43
Option/Short	Yes / Yes	LT Debt/Eq	1.17	EPS Q/Q	-55.20%	Payout	31.57%	Rel Volume	2.21	Prev Close	27.99
Sales Surprise	-3.10%	EPS Surprise	-0.39%	Sales Q/Q	-0.17%	Earnings	Aug 08 BMO	Avg Volume	2.62M	Price	27.54
SMA20	-2.97%	SMA50	-1.41%	SMA200	-2.61%	Trades		Volume	5,783,149	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
Aug-28-24 04:15PM	Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-26-24 06:16AM	Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): Its Been a Bit of a Bust, I Feel Badly (Insider Monkey)
Aug-23-24 05:32AM	Jim Cramer's Latest Lightning Round: Top 10 Stocks (Insider Monkey)
03:58PM	Loading…
Aug-17-24 03:58PM	Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? (Insider Monkey)
Aug-16-24 06:09PM	10 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-09-24 01:05AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:00AM	Royalty Pharma Reports Second Quarter 2024 Results (GlobeNewswire)
Jul-24-24 08:30AM	Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital (GlobeNewswire)
Jul-19-24 08:15AM	Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	Royalty Pharma Declares Third Quarter 2024 Dividend (GlobeNewswire)
Jul-15-24 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-02-24 07:44PM	Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now? (Insider Monkey)
06:58PM	Loading…
06:58PM	10 Best Undervalued Stocks To Buy Now (Insider Monkey)
Jun-26-24 06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 04:15PM	Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 05:15PM	Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes (GlobeNewswire)
May-28-24 07:10AM	Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million (GlobeNewswire)
May-27-24 06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-22-24 04:10PM	Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
04:00PM	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
May-20-24 02:41PM	7 Dividend Stocks to Buy at a 52-Week Low (InvestorPlace)
May-13-24 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 01:07AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 03:35PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
12:00PM	Loading…
12:00PM	Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
11:56AM	RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:10AM	Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates (Zacks)
07:00AM	Royalty Pharma Reports First Quarter 2024 Results (GlobeNewswire)
06:45AM	Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab (GlobeNewswire)
May-08-24 08:51AM	Why Earnings Season Could Be Great for Royalty Pharma (RPRX) (Zacks)
May-06-24 09:16AM	Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics (Zacks)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
10:01AM	Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-30-24 08:37AM	PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-19-24 08:15AM	Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-17-24 08:15AM	Royalty Pharma Declares Second Quarter 2024 Dividend (GlobeNewswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Feb-28-24 04:15PM	Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-17-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-16-24 03:30PM	Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:45AM	Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:04AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 11:08PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:58AM	Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis (GuruFocus.com)
07:30AM	Royalty Pharma Reports Q4 and Full Year 2023 Results (GlobeNewswire)
Jan-31-24 01:04AM	What Makes Royalty Pharma plc (RPRX) a Compelling Stock? (Insider Monkey)
Jan-30-24 04:15PM	Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 (GlobeNewswire)
Jan-19-24 08:15AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
Jan-08-24 07:00AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 05:30AM	Should You Sell Royalty Pharma plc (RPRX)? (Insider Monkey)
Nov-27-23 04:15PM	Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-13-23 08:10AM	Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program (GlobeNewswire)
08:00AM	Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program (Business Wire)
Nov-09-23 04:33PM	Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:15AM	The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 07:00AM	Royalty Pharma Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-19-23 07:59AM	Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi (GlobeNewswire)
Oct-16-23 04:15PM	Royalty Pharma Declares Fourth Quarter 2023 Dividend (GlobeNewswire)
Oct-11-23 04:15PM	Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023 (GlobeNewswire)
Sep-21-23 08:25AM	Royalty Pharma Appoints Eric Schneider as Chief Technology Officer (GlobeNewswire)
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:01PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
08:25AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 06:30AM	Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) (GlobeNewswire)
Aug-08-23 07:00AM	Royalty Pharma Reports Second Quarter 2023 Results (GlobeNewswire)
Jul-18-23 04:15PM	Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-17-23 04:15PM	Royalty Pharma Declares Third Quarter 2023 Dividend (GlobeNewswire)
Jun-18-23 08:58AM	Institutional owners may consider drastic measures as Royalty Pharma plc's (NASDAQ:RPRX) recent US$453m drop adds to long-term losses (Simply Wall St.)
Jun-07-23 08:15AM	Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-22-23 07:52PM	Goldman Sachs Likes These 2 Stocks, Insiders Just Poured Millions Into Them Heres Why You Might Want to Ride Their Coattails (TipRanks)
May-13-23 08:15AM	Here's Why We're Wary Of Buying Royalty Pharma's (NASDAQ:RPRX) For Its Upcoming Dividend (Simply Wall St.)
May-11-23 10:42AM	Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's (Simply Wall St.)
May-09-23 07:00AM	Royalty Pharma Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 04:15PM	Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-20-23 06:15AM	Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20 (Simply Wall St.)
Apr-17-23 08:15AM	Royalty Pharma Declares Second Quarter 2023 Dividend (GlobeNewswire)
Apr-13-23 09:01AM	Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire)
Apr-05-23 06:17AM	Is Royalty Pharma plc's (NASDAQ:RPRX) Recent Price Movement Underpinned By Its Weak Fundamentals? (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research)
Mar-27-23 07:30AM	Royalty Pharma Announces $1.0 Billion Share Repurchase Program (GlobeNewswire) +5.53%
Mar-23-23 07:00AM	Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million (GlobeNewswire)
03:00AM	PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million (Business Wire)
Mar-15-23 08:00AM	Royalty Pharma Raises Full Year 2023 Guidance (GlobeNewswire)
Mar-08-23 05:16AM	Optimism around Royalty Pharma (NASDAQ:RPRX) delivering new earnings growth may be shrinking as stock declines 3.5% this past week (Simply Wall St.)
Mar-01-23 08:15AM	Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments (GlobeNewswire)
Feb-15-23 07:00AM	Royalty Pharma Reports Q4 and Full Year 2022 Results (GlobeNewswire)
Feb-09-23 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-23 09:19AM	Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20 (Simply Wall St.)
Jan-18-23 08:25AM	Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023 (GlobeNewswire)
Jan-12-23 05:01AM	Royalty Pharma's (NASDAQ:RPRX) Shareholders Will Receive A Bigger Dividend Than Last Year (Simply Wall St.)
Jan-09-23 09:25AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:15AM	Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis Genetic Medicines and Commercial Readiness (GlobeNewswire)

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIGGS RORY B	Director	Jan 02 '24	Sale	28.52	235,200	6,707,081	254,899	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 03 '24	Sale	27.79	199,098	5,532,276	55,801	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 04 '24	Sale	27.55	35,702	983,504	20,099	Jan 04 05:16 PM
Avara Management Ltd	10% Owner	Dec 29 '23	Sale	28.04	65,803	1,845,406	2,477,520	Jan 03 04:31 PM
Avara Management Ltd	10% Owner	Dec 28 '23	Sale	28.20	209,863	5,918,934	2,543,323	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 27 '23	Sale	28.01	41,729	1,168,754	2,753,186	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 15 '23	Sale	28.01	10,229	286,499	2,794,915	Dec 19 04:30 PM
Avara Management Ltd	10% Owner	Dec 14 '23	Sale	28.91	364,441	10,534,276	2,805,144	Dec 15 04:31 PM
Avara Management Ltd	10% Owner	Dec 13 '23	Sale	28.95	307,935	8,916,012	3,169,585	Dec 15 04:31 PM

PROK

ProKidney Corp

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience